哮喘对生活质量量表（A-IQOLS）的影响在不同哮喘研究人群和人群亚群中的表现
2018/08/16
摘要
背景：哮喘对生活质量量表（A-IQOLS）的影响评估了哮喘对患者生活质量（QoL）的负面影响。它的标准测量误差是已知的，它具有强大的构造结构、收敛特性和分歧效度，并提供哮喘结果测量中独特的信息。
目的：表征A-IQOLS的心理测量特性以及在人口统计学和临床上不同的成人哮喘人群中的适用性。
方法：汇总来自五项独立哮喘研究的参与者的数据，以确定A-IQOLS评分的心理测量表现、总体和多种人口统计、疾病状态和研究亚组。数据样本范围为控制良好的中度哮喘患者到严重、控制不佳的哮喘患者。
结果：汇总样本（n = 597）平均年龄为45岁; 其中66％为女性，65％为白人，22％为非裔美国人，11％为西班牙裔，11％的学历为高中教育及以下。无论患者的人口统计学和临床特征如何，其潜在生命维度的评级重要性以及A-IQOLS评分与肺功能、症状、ACT、Juniper Mini-AQLQ和Marks AQLQ评分之间的关联非常相似。 A-IQOLS评分在个体研究样本中以及其他患者报告的症状和功能状态测量中进行区分。分布特性和基于目标的考量表明A-IQOLS最小临床有意义变化值（MID）在0.50左右，并且不小于0.33。
结论：A-IQOLS对于人口统计学和临床多样化患者的研究及临床转化均适用。
Performance of the Asthma Impact on Quality of Life Scale (A-IQOLS) in diverse asthma research populations and demographic sub-groups
Sandra R. Wilson, et al.
J Allergy Clin Immunol, 2018 May 3.
Abstract
Background：The Asthma Impact on Quality of Life Scale (A-IQOLS) assesses patientperceived negative effect of asthma on quality of life (QoL). Its standard error of measurement is known, it has strong construct, convergent, and divergent validity, and provides information that is unique among asthma outcome measures.
Objective：To characterize A-IQOLS’ psychometric properties and suitability for use in demographically and clinically diverse adult asthma populations.
Methods：Data from participants in five independent asthma studies, whose samples ranging from patients with well-controlled moderate asthma to patients with severe, poorly controlled asthma were pooled to determine the psychometric performance of A-IQOLS scores, overall and in multiple demographic, disease status, and study subgroups.
Results：Pooled sample (n = 597) age averaged 45 years; 66% were female, 65% were White, 22% African American, 11% Hispanic, and 11% had ≤ high school education. The rated importance of its underlying life dimensions and the associations between A-IQOLS scores and lung function, symptoms, ACT, Juniper Mini-AQLQ, and Marks AQLQ scores was very similar regardless of patient demographic and clinical characteristics. A-IQOLS scores discriminated among the individual study samples as well as other patient-reported symptom and functional status measures. Distribution and anchor-based considerations suggest an A-IQOLS minimum clinically important difference (MID) in the vicinity of 0.50, and not smaller than 0.33, scale score units.
Conclusion：A-IQOLS is valid for research, and potentially clinical, use in demographically and clinically diverse patients.
背景：哮喘对生活质量量表（A-IQOLS）的影响评估了哮喘对患者生活质量（QoL）的负面影响。它的标准测量误差是已知的，它具有强大的构造结构、收敛特性和分歧效度，并提供哮喘结果测量中独特的信息。
目的：表征A-IQOLS的心理测量特性以及在人口统计学和临床上不同的成人哮喘人群中的适用性。
方法：汇总来自五项独立哮喘研究的参与者的数据，以确定A-IQOLS评分的心理测量表现、总体和多种人口统计、疾病状态和研究亚组。数据样本范围为控制良好的中度哮喘患者到严重、控制不佳的哮喘患者。
结果：汇总样本（n = 597）平均年龄为45岁; 其中66％为女性，65％为白人，22％为非裔美国人，11％为西班牙裔，11％的学历为高中教育及以下。无论患者的人口统计学和临床特征如何，其潜在生命维度的评级重要性以及A-IQOLS评分与肺功能、症状、ACT、Juniper Mini-AQLQ和Marks AQLQ评分之间的关联非常相似。 A-IQOLS评分在个体研究样本中以及其他患者报告的症状和功能状态测量中进行区分。分布特性和基于目标的考量表明A-IQOLS最小临床有意义变化值（MID）在0.50左右，并且不小于0.33。
结论：A-IQOLS对于人口统计学和临床多样化患者的研究及临床转化均适用。
（复旦大学附属中山医院呼吸内科 罗锦龙 摘译 杨冬 审校）
（J Allergy Clin Immunol, 2018 May 3.）
（J Allergy Clin Immunol, 2018 May 3.）
Performance of the Asthma Impact on Quality of Life Scale (A-IQOLS) in diverse asthma research populations and demographic sub-groups
Sandra R. Wilson, et al.
J Allergy Clin Immunol, 2018 May 3.
Abstract
Background：The Asthma Impact on Quality of Life Scale (A-IQOLS) assesses patientperceived negative effect of asthma on quality of life (QoL). Its standard error of measurement is known, it has strong construct, convergent, and divergent validity, and provides information that is unique among asthma outcome measures.
Objective：To characterize A-IQOLS’ psychometric properties and suitability for use in demographically and clinically diverse adult asthma populations.
Methods：Data from participants in five independent asthma studies, whose samples ranging from patients with well-controlled moderate asthma to patients with severe, poorly controlled asthma were pooled to determine the psychometric performance of A-IQOLS scores, overall and in multiple demographic, disease status, and study subgroups.
Results：Pooled sample (n = 597) age averaged 45 years; 66% were female, 65% were White, 22% African American, 11% Hispanic, and 11% had ≤ high school education. The rated importance of its underlying life dimensions and the associations between A-IQOLS scores and lung function, symptoms, ACT, Juniper Mini-AQLQ, and Marks AQLQ scores was very similar regardless of patient demographic and clinical characteristics. A-IQOLS scores discriminated among the individual study samples as well as other patient-reported symptom and functional status measures. Distribution and anchor-based considerations suggest an A-IQOLS minimum clinically important difference (MID) in the vicinity of 0.50, and not smaller than 0.33, scale score units.
Conclusion：A-IQOLS is valid for research, and potentially clinical, use in demographically and clinically diverse patients.
上一篇：
ARIA Phase 4 (2018):采用移动技术改变变应性鼻炎和哮喘的多重发病率管理
下一篇：
重症哮喘问卷(SAQ)的构建与获批
